TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H).
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Gastrointestinal cancer
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms TMB-H basket TR
- 19 Sep 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Aug 2018 New trial record